Continuous ambulatory peritoneal dialysis in the United States: A three-year study  by Nolph, Karl D. et al.
Kidney International, Vol. 28 (1985), pp. 1 98—205
Continuous ambulatory peritoneal dialysis in the United States:
A three-year study
KARL D. NOLPH, SIDNEY J. CUTLER, SETH M. STEINBERG, and JOEL W. NOVAK
NIH-CAPD Registry, Clinical Coordinating Center, Division of Nephrology, University of Missouri Health Sciences Center, Columbia,
Missouri, and NIH-CAPD Registry, Data Coordinating Center, The EMMES Corporation, Potomac, Maryland, USA
Continuous ambulatory peritoneal dialysis in the United States: A
three-year study. This report of the NIH-supported National Continu-
ous Ambulatory Peritoneal Dialysis (CAPD) Registry summarizes data
on 7,404 patients treated with CAPD during the three-year period 1981
through 1983, or nearly one-half of patients treated in the USA who
were treated with CAPD during this time. While age and diabetes
mellitus impact on mortality, they appear to have a limited influence on
transfer or infection rate. There were 1.7 episodes of peritonitis, 0.7 exit
site/tunnel infections, and 0.3 catheter replacements reported per
patient year of observation. Patients averaged 10.2 hospital days per
year for CAPD complications and 22.3 hospital days per year for all
causes. Comparisons of these data with similar data reported for other
therapies are subject to variations in the distribution of population and
disease characteristics, as well as the length of the observation period.
Dialyse péritonéale continue ambulatoire aux Etats-Unis: Une étude de
trois ans. Ce rapport du National Continuous Ambulatory Peritoneal
Dialysis (CAPD) Registry sous l'egide du NIH resume les données
obtenues chez 7404 malades en CAPD pendant la période de trois ans,
1981 a 1983, soit presque Ia moitiC des malades traités aux Etats-Unis
par CAPD pendant ce temps. Bien que l'âge et le diabète sucré
influencent la mortalité, us semblent avoir une influence limitée sur les
taux de transfert ou d'infection. Ii y a eu 1,7 episodes de péritonite, 0,7
infections du point de sortie/du tunnel, et 0,3 changements de catheter
rapportés année d'observation-malade. Les malades comptaient en
rnoyenne 10,2jours d'hopital par an pour les complications de Ia CAPD
et 22,3 jours d'hospitalisation par an de toute autre cause. La
comparaison de ces données avec les données identiques rapportées
pour d'autres traitements est dépendante des variations de Ia distribu-
tion de Ia population et des caractéristiques de Ia maladie, ainsi que de
Ia durée de Ia période d'observation.
The United States Continuous Ambulatory Peritoneal Dialy-
sis (CAPD) Registry began in 1981. The Registry is a voluntary
registry supported by the National Institute of Arthritis, Diabe-
tes, and Digestive and Kidney Diseases of the National Insti-
tutes of Health; reports are prepared semiannually. Highlights
of previous reports have been published [1—31, and the Registry
is designed to monitor the demographic characteristics of and
outcome measures in patients treated by CAPD [4]. This report
examines all follow-up data for the period covering January 1,
1981, through December 31, 1983 (data collection cut-off, April
6, 1984). These data are of particular interest because they
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concern a substantial portion (estimated near 50%) of the
United States patients who were treated with CAPD during the
report period.
Most reports that examine morbidity as well as mortality are
either limited to small numbers of patients or are detailed
cross-sectional analyses of a cohort of patients. The value of
such studies is limited owing to the lack of longitudinal infor-
mation that is especially important in chronic illness. Even
longitudinal studies of short duration cannot provide informa-
tion for current and evolving therapy.
An ongoing registry addresses some of these problems. In
Europe and Australia and New Zealand, there are registries to
monitor nearly all patients on all forms of renal replacement
therapy [11. The United States does not have such a complete
registry. The CAPD Registry, sponsored by NIH, provides
ongoing monitoring of a therapy that is growing and evolving
rapidly.
Methods
During 1981, participation was solicited from all centers
offering CAPD, as identified by the Health Care Financing
Administration (HCFA). Since that time, officials of the Regis-
try have been present at professional conferences in a continu-
ing effort to enroll clinics in the program. When the Registry
began, only 13 centers participated on a pilot basis. This
number increased to 184 by the fourth quarter of 1981. Through
December, 1983, 270 clinics have participated in the program
[5]. Of the 270, 227 (84%) provided patient information current
through the end of 1983.
HCFA reports that as of December 31, 1983, 1,296 centers
were offering dialysis service and a total of 8,532 patients were
on CAPD [6]. The 227 centers that provided current follow-up
information to the CAPD Registry accounted for 3,751 patients,
44% of the national total.
Participation in the Registry requires registering patients and
submitting follow-up information at quarterly intervals, The
registration form records each patient's name, sex, race, date of
birth, date of first ESRD therapy, and date of first CAPD
exchange. Quarterly status reports provide data on each
patient's primary renal disease, occurrence of peritonitis or exit
site/tunnel infections, catheter replacements, hospitalizations,
and treatment status, for example, still on CAPD, transferred to
another modality, or deceased. The information on individual
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patients is confidential. Analytic and operational reports do not
identify individual patients or individual treatment centers.
The registration and follow-up forms are completed at the
clinic itself, generally by the CAPD nurse coordinator, then
mailed to the Data Coordinating Center (DCC) of the Registry.
The DCC provides clinics with a status form, to be completed
four times per year, for each patient on whom a registration
form was received. These forms are mailed to the clinics within
15 days of the end of each calendar quarter and clinics are
instructed to return the forms within four weeks.
This report is restricted specifically to those data that were
available for analysis by the cut-off date. At that time, patient
status reports were available for 7,404 CAPD patients. (An
additional 297 patients on CCPD are being monitored, but their
data are excluded from this report.) Of this total, 4,973 were
registered when they first began CAPD therapy (Class 1), and
2,431 had been on CAPD for varying lengths of time when their
treatment centers joined the registry program (Class 2). The
Class 1 patients are divided into two subgroups: 1A, no therapy
for ESRD prior to initiation of CAPD (1,804 patients); and 1B,
other therapy for ESRD prior to initiation of CAPD (3,169
patients). l'hus, Class 1 patients have data that reflect their
entire course of CAPD therapy. Since the Registry does not
attempt to obtain data retrospectively, which may diminish its
overall quality, data on Class 2 patients are limited to prospec-
tive information. Early experience with the Registry indicated
that information collected on specific therapies for Class lB
patients was incomplete for a substantial proportion of patients.
Thus, only the fact of prior therapy or no prior therapy is used
for analysis.
Unlike studies based on a national random sample in which
scientific selection procedures are used to assure representa-
tiveness of subjects with regard to important characteristics,
the National CAPD Registry does not represent necessarily the
experience of all patients on CAPD in the US, Selection biases
of unknown direction and magnitude are possible. If one were
to view the Registry as representing an incomplete census, then
it is possible to consider the data as a convenience sample, that
is, one to which making statistical inferences in the form of
standard statistical tests is inappropriate. In addition, given the
large numbers of patients who would be compared by means of
any tests, some small differences, even 1%, are statistically
significant, although unimportant clinically. Thus, it would be
misleading to present such findings in terms of traditional P
values. Consequently, we will refer to observed differences as
being either clinically significant or not, in order to address the
key issues.
When dealing with measures of morbidity, such as episodes
of peritonitis, exit site/tunnel infections, changes of catheter, or
hospitalization, it is standard practice to report these in terms of
rates of occurrence per patient years of observation [7]. For
patients who started CAPD at registration (Classes lA and 1B),
patient years of observation account for the total time elapsed
from date of initiation of CAPD to the date of the last status
report. For patients who started on CAPD prior to registering
(Class 2), patient years of observation extend from the date of
registration, that is, rates pertain only to the period under
observation in this program.
The probability of a patient developing a specific CAPD-
related complication, such as peritonitis, requiring hospitaliza-
tion due to a CAPD-related complication, or dying while on
CAPD is assessed by the life-table method. A death is reported
to the Registry if it occurred while a patient is on CAPD or
within two weeks of transfer to another therapy. A transfer is a
change to another dialysis modality with no intention to return
to CAPD, or a transfer of at least a four-week duration. The
graphs and supporting tables present the probability of a
specified event occurring over time, for example, within 6, 12,
or 24 months after initiation of CAPD. Different methods for
life-table analysis are used, depending on whether exact times
to occurrence of the outcome are noted [8] or whether the
occurrence of the outcome is known only to have been during a
particular interval of time [9]. Computation of such curves
requires computation of cumulative probabilities of failure, and
the technical details are explained best elsewhere [8, 9]. Be-
cause Class 2 patients are "survivors" from a larger group with
unknown mortality or morbidity, life tables are constructed
only with data on Class 1A and lB patients. This method can be
applied also to evaluating the probability of the second occur-
rence of a complication, conditional upon having experienced
the first occurrence.
A non-traditional statistical tool, herein referred to as a
"sample pattern-graph", is used in this report to display
visually the sequence of events occurring to a subset of pa-
tients. Its purpose is to illustrate patterns of morbidity and what
impact, if any, the patterns may have on treatment outcomes.
While no firm conclusions may be drawn using such a tech-
nique, it may be used to illuminate important points requiring
further investigation. To construct the graph (Fig. 1), a sample
of 50 patients was drawn by systematic sampling [10] from the
population of patients with an initial status report pertaining to
the fourth quarter of 1981, when the Registry program went into
full operation. Owing to the quarterly submission of data, the
events noted are presented at the midpoint of each calendar
quarter. About one-half the patients with an initial status report
pertaining to the fourth quarter of 1981 had begun therapy in the
previous quarter, which is indicated in the graph (Fig. 1).
Results
Patient demographic characteristics and primary diagnosis
are presented in Table 1. As shown, one-third of patients in the
Registry are more than 60 years of age, more than half are male,
three-fourths are white, and nearly two-thirds have one of four
major types of disease: chronic glomerulonephritis, diabetic
glomerulosclerosis, hypertensive renal disease, or polycystic
kidney disease. Data obtained from HCFA on 7,500 patients
treated by CAPD in 1983, shows 54% males, 23% 60 or more
years of age, and 18% black; although for Registry patients
accumulated over a three-year period, distributions are similar.
As Table 2 shows, 60% of patients were continuing on CAPD
therapy at the end of 1983. Among those who were no longer on
CAPD, the largest number (1,235) had been transferred to
hemodialysis, and another 1,045 had died while on CAPD.
Among those transferred to hemodialysis, Table 3 shows that a
substantial proportion (39.6%) did so for medical reasons such
as visual or manual impairment, and an additional 27.9% left
because of peritonitis considered to be excessive by the physi-
cians in charge. Slightly less than 10% transferred because the
therapy was unable to perform effectively its intended dialytic
function.
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Table 1. Patient characteristics, percentages in parentheses
Class
IA lB 2 Total
Age, years
 20
21 to 40
41 to 60
61+
Not reported
107 (5.9)
411 (22.8)
635 (35.2)
623 (34.5)
28 (1.6)
139 (4.4)
799 (25.2)
1,231 (38.8)
966 (30.5)
34 (1.1)
114
535
952
792
38
(4.7)
(22.0)
(39.2)
(32.6)
(1.6)
360 (4.8)
1,745 (23.6)
2,818 (38.1)
2,381 (32.2)
100 (1.4)
Sex
Male
Female
Not reported
1,003 (55.6)
773 (42.8)
28 (1.6)
1,721 (54.3)
1,414 (44.6)
34 (1.1)
1,364
1,029
38
(56.1)
(42.3)
(1.6)
4,088 (55.2)
3,216 (43.4)
100 (1.4)
Race/ethnicity
Black
White
Hispanic
Other/unknown
241 (13.4)
1,443 (80.0)
56 (3.1)
64 (3.5)
552 (17.4)
2,376 (75.0)
118 (3.7)
123 (3.9)
388
1,835
114
104
(16.0)
(75.5)
(4.7)
(4.3)
1181 (16.0)
5,654 (76.4)
278 (3.8)
291 (3.9)
Diagnosis
Chronic glomerulonephritis
Diabetic glomerulosclerosis
Hypertensive renal disease
Polycystic kidney disease
Other/unknown
287 (15.9)
548 (30.4)
277 (15.4)
95 (5.3)
597 (33,1)
716 (22.6)
604 (19.1)
489 (15.4)
230 (7.3)
1,130 (35.7)
577
421
389
216
830
(23.7)
(17.3)
(16.0)
(8.8)
(34.1)
1,580 (21.3)
1,573 (21.2)
1,155 (15.6)
539 (7.3)
2,557 (34.5)
Total 1,804 (100.0) 3,169 (100.0) 2,431 (100.0) 7,404 (100.0)
Using life-table methodology, we found that 22% of patients
transferred off CAPD within 12 months, and 15% died while on
CAPD within 12 months. The results are presented in a graph as
Figure 2, and displayed in Table 4 for subgroups relating to age
and diabetic status. Although we consider it improper to test for
differences, it is noteworthy that diabetics are shown to be at
substantially greater risk of dying while on CAPD, as are those
over the age of 60. In contrast, the probabilities for transfer are
similar for diabetics and non-diabetics, and are similar also for
the two age groups. Mortality and transfer probabilities were
similar for the two sexes.
Life-table analyses were used also for the occurrence of the
three significant complications monitored by the Registry. As
shown in Figure 3, by the end of 12 months, these patients had
approximately a 20% risk of needing a catheter replacement, a
40% risk of developing an exit site/tunnel infection, and a 66%
risk of developing peritonitis. The risk of at least one of these
complications occurring was almost 80% by one year. Associ-
ated with these risks, there was a 57% chance of hospitalization
for some CAPD-related complication within twelve months
(Fig. 4). Expressed in terms of rates per patient year of
observation, occurrences of these problems amounted to 1.7
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Fig. 1. Variation of patient experience: Sample of 50
patients. Symbols are: F, CAPD initiated; —x, on CAPD
at last report; , no status report for quarter; 0,
peritonitis; , exit-site infection; 0, catheter
replacement; x, death; •, transfer to hemodialysis or
IPD; A, transplant; , kidney function return.
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Number Percentage
Continuing on CAPD 4,398 60.3
Transferred to hemodialysis 1,235 16.9
Transferred to intermittent
peritoneal dialysis 106 1.5
Dialysis discontinued with no
return of kidney function 29 0.4
Kidney function returned 57 0.8
Received transplant 425 5.8
Died while on CAPD 1,045 14.3
Total 7,295a 100.0
Note: The data in this table do not account for the length of time
patients were on CAPD prior to the last reported status.
a Information not available for 109 patients.
Number Percentage
Excessive peritonitis 344 27.9
Other medical reasons, including
visual or physical impairment 489 39.6
CAPD did not meet
fluid/biochemical standards 122 9.9
Patient/family choice 163 13.2
Socioeconomic factors 14 1 .
Other reasons/unknown 103 8.3
Total 1235 100.0
Months
Fig. 2. Probability of transfer to hemodialysis or IPD, leaving dialysis
with no return of kidney function, or dying while on CAPD. Symbols
are: —
— —, transferring to hemodialysis or IPD; , leaving
dialysis with no return of kidney function; , dying while on CAPD.
Table 4. Cumulative probability of transfer off CAPD or dying while
on CAPD, %
Months from
starting CAPD
All Diabetics Non-
patients onlya diabetics
Age
20 to 59
years
Age
 60
years
6
Transfer off CAPDb, %
11 1011 11 11
12 22 23 22 22 22
18 30 33 29 27 29
24 39 41 39 41 38
6
Dying while on CAPD, %
5 127 11 6
12 15 24 12 10 24
18 20 32 17 15 31
24 26 41 23 21 38
6
Transfer or dyingc, %
16 2017 21 16
12 33 41 31 30 40
18 44 54 41 41 51
24 55 64 52 53 61
a Patients with diabetic glomerulosclerosis.
b Includes patients transferred to hemodialysis or IPD or discontin-
ued dialysis with no return of kidney function.
The probabilities in the first two sections above do not add to the
probabilities in the last section, which pertains to the probability of
either transfer off CAPD or dying while on CAPD, whichever occurred
first. In computing the probabilities in the first section, patients who
died while on CAPD were withdrawn from the risk of transfer, at time
of death. In the second section, patients transferred off CAPD were
withdrawn from the risk of dying at time of transfer.
Months
Fig. 3. Probability of first complication of CAPD by type of complica-
tion. Symbols are: , any one (whichever complication occurred
first); —
— —, peritonitis; , exit site/tunnel infection; , cath-
eter replacement.
Table 2. Last reported status of patients in the Registry
Table 3. Reasons for transfer to hemodialysis
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episodes of peritonitis, 0.7 exit site/tunnel infections, and 0.3
catheter replacements. The average length of hospitalization
due to CAPD complications is 10.2 days per patient year; for all
hospitalizations, irrespective of cause, the rate is 22.3 days per
patient year.
While the life tables discussed so far have all pertained to the
time of the first occurrence of some outcome, the same meth-
odology was applied to identify times to successive episodes of
each condition (Table 5), Median times to successive episodes
decreased as the ordinal number of the complication increased,
with the most marked decrease in interval noted for exit
site/tunnel infections, where the median time to the first occur-
rence was 17.7 months and only 7.0 months from the first to the
second. For peritonitis, the median was 7.3 months to the first
incidence, but 4.6 from the first to the second.
Since peritonitis is noted most frequently among reportable
complications, we have examined the occurrence of this prob-
lem in terms of differences in patient characteristics. Table 6
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Months
Fig. 4. Probability of first hospitalization for CAPD-related com-
plications.
Patients
Type of complication
Median
months
at riska
number
Any complication
Time to first occurrence 4.5 4,973
Time from first to second occurrence 3.0 2,577
Time from second to third occurrence 3.0 1,314
Time from third to fourth occurrence 2.7 607
Peritonitis
Time to first peritonitis 7.3 4,973
Time from first to second peritonitis 4.6 2,042
Time from second to third peritonitis 4.2 864
Time from third to fourth peritonitis 3.7 326
Exit site/tunnel infection
Time to first infection 17.7 4,973
Time from first to second infection 7.0 1,250
Time from second to third infection 5.4 435
Time from third to fourth infection 4.8 153
Catheter replacement
Time to first catheter change > 24 4,973
Time from first to second change > 24 613
Time from second to third change > 24 86
summarizes the experience of selected patient groups with
respect to the first episode of peritonitis. The nature of the
primary renal disease influences the patient's risk of developing
peritonitis, particularly as reflected in the median time to the
first episode. Among the four most common renal diseases, the
medians varied from 6.3 to 8.2 months (Table 6)
The patient's status at last report is related clearly to the
length of time to first peritonitis. Patients who were transferred
to hemodialysis or IPD had a short median time (4.6 months) to
first episode of peritonitis, compared to 8.2 months for patients
continuing on CAPD as of the last status report. There was little
difference between the sexes, but there were marked differ-
ences with respect to age and race.
In general, the relationships between time until the first
Table 6. Time to successive episodes of peritonitis for selected
patient groups
Median number of months to
successive episodes
First
To first to second
Second
to third
Last reported status
Continuing on CAPD 8.2 (3,076)a 5.7 (1,228)
Transferre&' 4.6 (851) 2.9 (399)
Died 6.2 (613) 3.2 (254)
Primary renal disease
Chronic glomerulonephritis 7.4 (1,002) 5.8 (427)
Diabetic glomerulosclerosis 6.5 (1,151) 4.3 (463)
Hypertensive renal disease 6.3 (766) 4.1 (346)
Polycystic kidney(s) 8.2 (325) 4.5 (144)
Age
5.5 (525)
2.7 (174)
2.6 (95)
4.3 (169)
4.4 (197)
4.3 (148)
3.0 (67)
20 to 59 years 7.4 (3,076) 5.0 (1,307)
60 years and over 6.7 (1,589) 4.5 (585)
Race
4.7 (555)
3.8 (243)
White 7.0 (3,819) 4.8(1,514)
Black 4.8 (793) 3,7 (391)
Race and age
4.8(627)
C
White, 20 to 60 8.3 (2,400) 5.0 (941)
White, 60 + 7.0 (1,213) 5.0 (477)
Black, 20 to 60 4.7 (586) 3.7 (287)
Black, 60 + 5.0 (170) 3.7 (81)
Sex
C
C
C
C
Male 7.2 (2,724) 4.8(1,133)
Female 6.7 (2,187) 4.3 (896)
4.8(476)
4.0 (383)
episode and between first and subsequent episodes correlates
well. For example, the interval between episodes for patients
transferred off CAPD were shorter consistently than for pa-
tients continuing on CAPD; the interval between episodes for
patients 60 years and older were shorter consistently than for
patients 20 to 59 years.
Finally, it must be remembered that all of these analyses so
far have not attempted to examine outcomes in terms of
individual patient differences. Figure 1 demonstrates, in a
schematic fashion, that patients have widely varying experi-
ences on CAPD, both in terms of complications experienced
and their ability to remain on therapy. For example, while
patient number 14 has had multiple episodes of peritonitis and
continues to receive CAPD, patient 42 had one episode of
peritonitis and transferred then to another maintenance ther-
apy. This analysis is presented to show that many questions,
while answered for large groups of patients, may not pertain
when individual patients are considered.
Discussion
These results in 7,404 patients on CAPD during a three-year
period show peritonitis and transfer as major problems to be
addressed. Although age and diabetes influence mortality, they
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Table 5. Median number of months between successive episodes of
CAPD-related complications, by type of complication
a Number of patients at risk are in parentheses.
b Transferred to hemodialysis or IPD or left dialysis without return of
kidney function.
C Insufficient data for calculation.
a The number of patients at risk decreases for two reasons: some
patients are taken off CAPD or die, and patients are not at risk for a
second episode unless they have had an initial one, and are not at risk
for a third unless they have had a second, and so forth.
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have minimal association with transfer. The probability of
developing peritonitis first was greater among blacks compared
to whites.
Information from the Health Care Financing Administration
indicates that as of December 31, 1980, 2,334 patients were on
CAPD, out of 52,364 total dialysis patients (4.5%) [6]. As of
December 31, 1983, there were 8,532 patients on CAPD, out of
71,987 total dialysis patients (11.9%) [6]. Thus, the proportion
of patients dialyzing with CAPD has shown large growth over
the three-year period 1980 to 1983. The Health Care Financing
Administration (HCFA) does not monitor exact dates when
patients begin or stop given therapies. Nevertheless, follow-up
data in 7,404 patients participating in the CAPD Registry
represents a substantial portion of the national CAPD popula-
tion during this time period.
We cannot guarantee that the Registry population is repre-
sentative of the entire national CAPD population. Age, sex and
primary renal disease characteristics of the total patients in the
HCFA data are not available. It is possible that those patients in
the Registry represent younger, healthier patients from more
experienced centers with better results. Against such a bias,
however, are several factors. First, the magnitude of our
population represents a sizable proportion of the total popula-
tion, and this reduces the risk of a selective process. Second, all
CAPD centers have been encouraged to participate in the
Registry at meetings, in publications, and by direct correspon-
dence. Third, individual analyses of each center's experiences
are carried out and returned to that center. These results show
that the centers are very heterogeneous, with results much
better or much worse than Registry averages. Fourth, the
Registry results are very similar to results being reported by the
European and Australia-New Zealand Registries, detailed
below.
Another potential weakness of the Registry could result if
participating centers do not register their worst patients. How-
ever, in October, 1983, a special questionnaire study and
comparisons with other data sources suggest that participating
centers register in excess of 97% of their CAPD case loads.
We hesitate to compare our results with those of others for
CAPD or other forms of renal replacement therapy. It is difficult
to interpret comparisons of data from different time periods
using different data collection techniques in populations with
variable patient mixes. CAPD results have been improving
progressively from year to year in Europe and Australia.
Definitions of death and drop-out from therapy differ from study
to study. The percentages of elderly and diabetic patients
influence outcomes markedly. With these precautions in mind,
we will cite results from several other studies performed over
the same time period as our report.
In 705 patients who began CAPD in 1981 in Europe, two-year
actuarial patient survival was 92% and actuarial technique
survival (those who did not die or transfer) was 67% [11].
In contrast to the high survival and technique survival
probabilities in Europe, in Australia and New Zealand, over the
period from 1978 to 1982, two-year actuarial patient survival in
590 patients starting CAPD was 79.7%, while two-year actuarial
technique success was 37.3% [12]. Comparable figures for
hemodialysis in general (1,903 patients) were 83.2 and 63.1%,
respectively; of these patients, 873 were on home hemodialysis
and respective survivals were 87.7 and 74.6%. For those who
started CAPD after 1981 (285 patients), the probability of
continued survival without transferring at two years was 52.3%
[12].
Other studies from the US and Canada have produced a
variety of findings. Data from the Missouri Kidney Program for
all patients on renal replacement therapy in Missouri (dialysis
and transplantation combined) shows that two-year actuarial
patient survival overall in 3,575 patients treated during the past
10 years was 66.3% [13]. Results in subgroups were: diabetics
(57%); patients with glomerulonephritis (86.2%); patients over
60 (55%); patients 20 to 39 years (80%). Age and diabetes have
a marked impact on outcome, regardless of the form of therapy.
Experiences in Seattle were reviewed recently [14]. Two-
year actuarial patient survival in 328 patients on home
hemodialysis was 92%. Although survivals were not compared
for various forms of therapy, hospital days per year were
compared. The hospital days per year for home hemodialysis,
center hemodialysis, and CAPD were 9.2, 19.3, and 19.7 days
per year, respectively, presumably representing different pa-
tient mixes.
At the 1983 national meeting of the American Society for
Artificial Internal Organs, invited speakers on a morbidity and
mortality panel compared outcomes in a standard population.
This population was to include those aged 20 to 59 years,
without diabetes, without malignancy, without major cardio-
vascular disease, and without any major systemic illness other
than primary renal disease. Our Registry participated in this
panel and reported an actuarial patient survival of 92% at 15
months and an actuarial technique success of 74% at 18 months
in a standard population on CAPD [2]. Results from the Toronto
Western Hospital revealed actuarial patient and technique
survivals of 82 and 65% in the total CAPD population (210
patients) and 100 and 87% in the CAPD standard population (59
patients) [15]. A report from France cited standard population
results for two-year actuarial patient survival and two-year
actuarial technique success as follows: center hemodialysis (91
patients), 95 and 80%; home dialysis (87 patients), 99 and 92%;
CAPD (20 patients), 92 and 50% [16]. Six of eight patients
transferred from CAPD because of ultrafiltration or clearance
problems. Such problems have been frequent in France and
may, in part, relate to the use of certain brands of dialysis
solution [17]. Shapiro and Umen reported two-year actuarial
patient survivals on hemodialysis of 92% in patients less than 61
years (362 patients), and 80% in those over 61 years (310
patients), respectively [18].
A five-year report of cumulative survivals from the Renal
Network Coordinating Council of the Upper Midwest (End-
Stage Renal Disease Network 7, Minneapolis, Minnesota,
USA) again confirmed that age and diabetes have profound
effects on patient survivals [19]. In a standard population,
two-year actuarial patient survivals were 92% for CAPD, 96%
for center hemodialysis, and 96% for home hemodialysis.
The Canadian Renal Failure Registry reported results with
renal replacement therapies during 1981 and 1982 [20]. Two-
year actuarial survival in non-diabetic CAPD patients (596
patients) was 80%, while cumulative technical success was
52%. Results in 1,161 non-diabetics on hemodialysis showed an
actuarial patient survival of 79% at two years and a technical
success of 59%.
Thus, in general, USA Registry results for CAPD mortality
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and drop-out fall within the ranges of other reports. Compari-
Sons with other therapies are variable, but tend to show similar
mortalities with comparable populations, but higher drop-out
with CAPD. CAPD drop-out rates are showing decreasing
trends in Europe and Australia-New Zealand. Higher drop-out
rates with CAPD than with hemodialysis may reflect patient
selection, recurring peritonitis, loss of ultrafiltration (Europe),
and the ease of transfer from home to center.
Peritonitis rates have received much attention. The Registry
average of 1.7 episodes of peritonitis per patient year and a
median of 7.3 months to the first episode of peritonitis are not as
good as results from some very experienced centers. For
example, a recent report from the University of Toronto
Collaborative Dialysis Group revealed a peritonitis rate in 1982
of one episode every 14.1 patient months [21]. A report sum-
marizing six years of experience with peritonitis at the Univer-
sity of Missouri revealed a peritonitis rate of 1.2 episodes per
patient year during 1982 [221.
The Registry suggests that race influences the risk of perito-
nitis. Age may have an effect, but it is much less striking than
race. A recent report from South Africa, based on 88 patients
treated by CAPD during a four-year period, reports an overall
incidence of peritonitis in whites as one every 4.5 patient
months, compared to a very high incidence in blacks of one
every 1.6 patient months [23]. One report notes a higher
incidence of peritonitis in low-income patients [241. Information
available to the Registry does not allow us to determine whether
environmental, cultural, or immunological factors may contrib-
ute to the racial differences. Etiologies of renal disease, sex,
and diabetes mellitus have had no obvious impact on infection
rates.
Currently, the Registry does not publish information about
quality of life with CAPD, as compared with other renal
replacement therapies. A recent study by Simmons, Anderson,
and Comstra suggests that CAPD patients show more favorable
adjustment than hemodialysis patients in activities, self-ratings
of health, self-esteem, general well-being, and vocational reha-
bilitation [25]. On almost all measures, transplant patients
appear to have the highest quality of life, however. In a recent
summary of the National Kidney Dialysis and Kidney Trans-
plantation Study sponsored by the Health Care Financing
Administration [231, CAPD/CCPD patients showed slightly
higher subjective quality of life scores than center hemodialysis
patients, but both were below transplant patients. Forty-eight
percent of CAPD/CCPD patients, as compared to 41% of
in-center hemodialysis patients, were able to carry on normal
activity with minor signs of symptoms of disease. Vigorous
activity was limited in 85% of in-center hemodialysis patients
and 93% of CAPD/CCPD patients. Twenty-one percent of
center hemodialysis patients were employed part time or full
time, while 16% of CAPD/CCPD patients were in this status in
this study [26].
In summary, comparisons of morbidity, mortality, and qual-
ity of life between therapies in available reports are all subject
to population, collection technique, and time period biases.
However, if sustained differences between therapies seem
apparent from these numerous efforts, perhaps randomized
prospective trials would be justified and supported.
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